Patents Examined by Maria B Marvich
-
Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
Patent number: 8105574Abstract: A recombinant vector comprises simian adenovirus sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus gene(s) is also disclosed. Methods of using the vectors and cell lines are provided.Type: GrantFiled: June 19, 2007Date of Patent: January 31, 2012Assignee: The Trustees of the University of PennsylvaniaInventors: James M Wilson, Guangping Gao, Soumitra Roy -
Patent number: 7968341Abstract: The present invention relates to a method of sequence-specific recombination of DNA in eukaryotic cells, comprising the introduction of a first DNA comprising a nucleotide sequence containing at least one recombination sequence into a cell, introducing a second DNA comprising a nucleotide sequence containing at least one further recombination sequence into a cell, and performing the sequence specific recombination by a bacteriophage lambda integrase Int.Type: GrantFiled: November 28, 2003Date of Patent: June 28, 2011Assignees: Boehringer Ingelheim Pharma GmbH & Co KGInventors: Peter Dröge, Barbara Enenkel
-
Patent number: 7906111Abstract: Sequences of novel adeno-associated virus capsids and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles. AAV-mediated delivery of therapeutic and immunogenic genes using the vectors of the invention is also provided.Type: GrantFiled: September 30, 2004Date of Patent: March 15, 2011Assignee: The Trustees of the University of PennsylvaniaInventors: James M. Wilson, Guangping Gao, Mauricio R. Alvira, Luc H. Vandenberghe
-
Patent number: 7884085Abstract: AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to prevent an autoimmune diabetes condition in NOD mice in vivo and in situ. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.Type: GrantFiled: May 12, 2005Date of Patent: February 8, 2011Assignees: Baxter International Inc., Baxter Healthcare S.A., University of Pittsburgh-of the Commonwealth System of Higher EducationInventors: Larry R. Brown, Vered Bisker-Leib, Terrence L. Scott, Debra Lafreniere, Jennifer Machen, Nick Giannoukakls
-
Patent number: 7851218Abstract: The present invention provides cell lines for the production of E1-deleted adenovirus (rAd) vectors that complement E1A and E1B functions. The present invention also provides cell lines for the production of E1- and E2-deleted adenovirus vectors that complement E1A, E1B and E2B polymerase functions. The invention provides particular cell lines that complement E1A function by insertion of an E1A sequence containing mutations in the 243R and 289R proteins and an E1B sequence comprising the E1B-55K gene. Production yields in the resulting producer cell lines, designated SL0003 and SL0006, were similar to those obtained from 293 cells without generation of detectable recombinant replication competent adenovirus (“RCA”).Type: GrantFiled: December 12, 2005Date of Patent: December 14, 2010Assignee: Schering CorporationInventors: John A. Howe, Ken N. Wills, Robert Orville Ralston, II, Scott Joseph Sherrill
-
Patent number: 7846454Abstract: The present invention discloses nucleic acid sequences which encode infectious hepatitis C viruses and the use of these sequences, and polypeptides encoded by all or part of these sequences, in the development of vaccines and diagnostics for HCV and in the development of screening assays for the identification of antiviral agents for HCV.Type: GrantFiled: April 9, 2007Date of Patent: December 7, 2010Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Masayuki Yanagi, Jens Bukh, Suzanne U. Emerson, Robert H. Purcell
-
Patent number: 7846732Abstract: The present invention relates to a method of sequence-specific recombination of DNA in eukaryotic cells, comprising the introduction of a first DNA comprising a nucleotide sequence containing at least one recombination sequence into a cell, introducing a second DNA comprising a nucleotide sequence containing at least one further recombination sequence into a cell, and performing the sequence specific recombination by a bacteriophage lambda integrase Int.Type: GrantFiled: November 17, 2005Date of Patent: December 7, 2010Assignees: Boehringer Ingelheim Pharma KGInventors: Peter Dröge, Barbara Enenkel
-
Patent number: 7820441Abstract: The present invention relates to methods and compositions for the production of viral vectors. In particular, the present invention provides methods and compositions for faster, higher titer and higher purity production of viral vectors (e.g. adenoviral vectors). In some embodiments, the present invention provides gutted and helper viruses with identical or similar termini. In other embodiments, the present invention provides terminal protein linked adenoviral DNA. In certain embodiments, the present invention provides template extended adenoviral DNA.Type: GrantFiled: September 21, 2001Date of Patent: October 26, 2010Assignee: The Regents of the University of MichiganInventors: Jeffrey S. Chamberlain, Dennis J. Hartigan-O'Connor
-
Patent number: 7759467Abstract: A method to increase the efficiency of transduction of hematopoietic and other cells by retroviruses includes infecting the cells in the presence of fibronectin or fibronectin fragments. The fibronectin and fibronectin fragments significantly enhance retroviral-mediated gene transfer into the cells, particularly hematopoietic cells including committed progenitors and primitive hematopoietic stem cells. The invention also provides improved methods for somatic gene therapy capitalizing on enhanced gene transfer, hematopoietic cellular populations, and novel constructs for enhancing retroviral-mediated DNA transfer into cells and their use.Type: GrantFiled: June 15, 2006Date of Patent: July 20, 2010Assignee: Indiana University Research and Technology CorporationInventors: David A Williams, Vikram P Patel
-
Patent number: 7749493Abstract: The present invention provides methods and vector systems for the generation of chimeric recombinant adenoviruses. These hybrid adenoviruses contain a genome that is derived from different adenovirus serotypes. In particular, novel hybrid adenoviruses are disclosed with improved properties for gene therapy purposes. These properties include: a decreased sensitivity towards neutralizing antibodies, a modified host range, a change in the titer to which adenovirus can be grown, the ability to escape trapping in the liver upon in vivo systemic delivery, and absence or decreased infection of antigen presenting cells (APC) of the immune system, such as macrophages or dendritic cells. These chimeric adenoviruses thus represent improved tools for gene therapy and vaccination since they overcome the limitations observed with the currently used serotype subgroup C adenoviruses.Type: GrantFiled: August 18, 2005Date of Patent: July 6, 2010Assignee: Crucell Holland B.V.Inventors: Menzo Havenga, Ronald Vogels, Abraham Bout
-
Patent number: 7727522Abstract: The invention relates to retroviral vectors (known as lentiviral vectors), which are used to transfer genes into cells that are at cell cycle stage G0, to methods for their production and to the use thereof for transferring genes into mammalian cells. Said vectors are derived from SIVsmmPBj14 (simian immunodeficiency virus) of the sooty mangabey monkey, strain PBj 14.Type: GrantFiled: April 3, 2003Date of Patent: June 1, 2010Inventors: Klaus Cichutek, Michael Muehlebach, Matthias Schweizer
-
Patent number: 7709224Abstract: Vector constructs for expression of two or more functional proteins or polypeptides under operative control of a single promoter and methods of making and using the same are described. The vectors comprise a self-processing cleavage site between each respective protein or polypeptide coding sequence. The vector constructs include the coding sequence for a self-processing cleavage site and may further include an additional proteolytic cleavage sequence which provides a means to remove the self processing peptide sequence from expressed protein(s) or polypeptide(s). The vector constructs find utility in methods for enhanced production of biologically active proteins and polypeptides in vitro and in vivo.Type: GrantFiled: April 26, 2004Date of Patent: May 4, 2010Assignee: Biosante Pharmaceuticals, Inc.Inventors: Jianmin Fang, Karin Jooss, Andrew Simmons, Jing-Jing Qian
-
Patent number: 7662623Abstract: Vector constructs for expression of two or more functional proteins or polypeptides under operative control of a single promoter and methods of making and using the same are described. The vectors comprise a self-processing cleavage site between each respective protein or polypeptide coding sequence. The vector constructs include the coding sequence for a self-processing cleavage site and may further include an additional proteolytic cleavage sequence which provides a means to remove the self processing peptide sequence from expressed protein(s) or polypeptide(s). The vector constructs find utility in methods for enhanced production of biologically active proteins and polypeptides in vitro and in vivo.Type: GrantFiled: October 26, 2007Date of Patent: February 16, 2010Assignee: BioSante Pharmaceuticals, Inc.Inventors: Jianmin Fang, Karin Jooss, Andrew Simmons, Jing-Jing Qian
-
Patent number: 7638331Abstract: The present invention provides methods and constructs for selectively expressing an Apoptosis-Inducing Gene (AIG) in a population of cells that overexpress cyclooxygenase-2 (COX-2) to induce apoptosis in the cell. To achieve this goal a chimeric gene construct is used that comprises a cyclooxygenase-2 promoter (COX-2 promoter) that is operably linked to at least one AIG such that the COX-2 promoter is activated in cells that overexpress COX-2, thereby resulting in transcription and translation of the AIG, which in turn activates apoptosis in the cell. Thus, apoptosis is selectively induced in only those cells capable of overexpressing COX-2.Type: GrantFiled: December 23, 2004Date of Patent: December 29, 2009Assignee: The Administration of the Tulane Rducation FundInventors: W. Terrance Godbey, Anthony Atala
-
Patent number: 7608448Abstract: The present invention relates to a vector comprising sequences that permit direct transfer of the vector from one prokaryotic cell to another, such as by intergeneric conjugation. The invention also relates to methods of making and using the vector.Type: GrantFiled: March 28, 2003Date of Patent: October 27, 2009Assignee: WyethInventor: Nathan Magarvey
-
Patent number: 7588934Abstract: A nucleotide sequence encoding a fumarate hydratase C and a method for preparing succinic acid using the same, more particularly, a fumarate hydratase C having the activity of converting malate to fumarate, a fumC nucleotide sequence encoding the fumarate hydratase C, a recombinant vector containing the nucleotide sequence, a microorganism transformed with the recombinant vector, and a method for preparing succinic acid using the transformed microorganism.Type: GrantFiled: September 16, 2005Date of Patent: September 15, 2009Assignee: Korea Advanced Insitute of Science and TechnologyInventor: Sang Yup Lee
-
Patent number: 7560527Abstract: The invention concerns an adenovirus fiber modified by mutation of one or several residues of the region included between residues 491 and 505 of SEQ ID NO: 1, the viral particles or pseudo-particles comprising such a fiber and their uses.Type: GrantFiled: November 23, 2000Date of Patent: July 14, 2009Assignee: Transgene S.A.Inventors: Valérie Legrand, Philippe Leissner
-
Patent number: 7504210Abstract: Cellular mRNA-protein (mRNP) complexes are partitioned in vivo by contacting a biological sample with at least one ligand that specifically binds at least one component of a mRNP complex. Suitable biological samples comprise at least one mRNA-protein (mRNP) complex and include cell cultures, cell extracts, and whole tissue, including tumor tissue. Ligands include antibodies that specifically bind RNA-binding or RNA-associated proteins present in the mRNP complex. The mRNP complex is separated by binding the ligand with a binding molecule specific for the ligand, where the binding molecule is attached to a solid support. The mRNP complex is collected by removing the mRNP complex from the solid support. After collecting the mRNP complex, the mRNA bound within the complex may be characterized and identified. Subsets of the total mRNA population of a cell may accordingly be characterized, and a gene expression profile of the cell obtained.Type: GrantFiled: July 29, 2003Date of Patent: March 17, 2009Assignee: Ribonomics, Inc.Inventors: Jack D. Keene, Scott A. Tenenbaum, Craig C. Carson
-
Patent number: 7498024Abstract: Single vector constructs for expression of an immunoglobulin molecule or fragment thereof and methods of making and using the same are described. The vectors comprise a self-processing cleavage sequence between a first and second immunoglobulin coding sequence allowing for expression of a functional antibody molecule using a single promoter. The vector constructs include the coding sequence for a self-processing cleavage site and may further include an additional proteolytic cleavage sequence which provides a means to remove the self processing peptide sequence from an expressed immunoglobulin molecule or fragment thereof. The vector constructs find utility in methods for enhanced production of biologically active immunoglobulins or fragments thereof in vitro or in vivo.Type: GrantFiled: April 26, 2004Date of Patent: March 3, 2009Assignee: Cell Genesys, Inc.Inventors: Jianmin Fang, Karin Jooss, Jing-Jing Qian
-
Patent number: 7491539Abstract: The present invention relates to a method of sequence-specific recombination of DNA in eukaryotic cells, comprising the introduction of a first DNA comprising a nucleotide sequence containing at least one recombination sequence into a cell, introducing a second DNA comprising a nucleotide sequence containing at least one further recombination sequence into a cell, and performing the sequence specific recombination by a bacteriophage lambda integrase Int.Type: GrantFiled: December 5, 2002Date of Patent: February 17, 2009Assignee: Boehringer Ingelheim Pharma KGInventors: Peter Dröge, Barbara Enenkel